CN101778630A - 用于治疗脂肪肝的包括西洛他唑的喹诺酮衍生物 - Google Patents

用于治疗脂肪肝的包括西洛他唑的喹诺酮衍生物 Download PDF

Info

Publication number
CN101778630A
CN101778630A CN200880024072A CN200880024072A CN101778630A CN 101778630 A CN101778630 A CN 101778630A CN 200880024072 A CN200880024072 A CN 200880024072A CN 200880024072 A CN200880024072 A CN 200880024072A CN 101778630 A CN101778630 A CN 101778630A
Authority
CN
China
Prior art keywords
fatty liver
cilostazol
quinolone
salt
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880024072A
Other languages
English (en)
Chinese (zh)
Inventor
中岛淳
藤田浩司
米田正人
向田修
市川贵子
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Publication of CN101778630A publication Critical patent/CN101778630A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN200880024072A 2007-07-11 2008-07-09 用于治疗脂肪肝的包括西洛他唑的喹诺酮衍生物 Pending CN101778630A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2007181760 2007-07-11
JP181760/2007 2007-07-11
PCT/JP2008/062771 WO2009008539A1 (en) 2007-07-11 2008-07-09 Carbostyril derivatives including cilostazol for treating fatty liver

Publications (1)

Publication Number Publication Date
CN101778630A true CN101778630A (zh) 2010-07-14

Family

ID=39689465

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880024072A Pending CN101778630A (zh) 2007-07-11 2008-07-09 用于治疗脂肪肝的包括西洛他唑的喹诺酮衍生物

Country Status (9)

Country Link
US (2) US8642618B2 (enExample)
EP (1) EP2162134A1 (enExample)
JP (2) JP5558348B2 (enExample)
KR (2) KR20150038739A (enExample)
CN (1) CN101778630A (enExample)
AR (1) AR067446A1 (enExample)
CA (1) CA2691632A1 (enExample)
TW (1) TW200908973A (enExample)
WO (1) WO2009008539A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101094934B1 (ko) * 2010-10-22 2011-12-15 영남대학교 산학협력단 실로스타졸을 유효성분으로 함유하는 알코올성 간질환 치료 또는 예방용 약학조성물
EP3263705A1 (en) * 2016-06-28 2018-01-03 DKFZ Deutsches Krebsforschungszentrum Treatments of non-alcoholic steatohepatitis (nash)
CN110366425A (zh) 2016-12-15 2019-10-22 泰伦基国际有限公司 一种预防动脉粥样硬化及其并发症的方法
WO2018108161A1 (zh) 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种预防和治疗肥胖症的方法和药物
EP3556385A4 (en) 2016-12-15 2020-12-30 Talengen International Limited PROCESS FOR ALLEGING HEART DISEASE
WO2022240783A1 (en) * 2021-05-11 2022-11-17 Regeneron Pharmaceuticals, Inc. Methods of treating liver diseases with phosphodiesterase 3b (pde3b) inhibitors
AU2022339755A1 (en) * 2021-08-31 2024-02-22 Regeneron Pharmaceuticals, Inc. Treatment of liver diseases with camp responsive element binding protein 3 like 3 (creb3l3) inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3944257B2 (ja) * 1995-12-07 2007-07-11 大塚製薬株式会社 肝実質細胞増殖因子産生増加剤

Also Published As

Publication number Publication date
US20110039887A1 (en) 2011-02-17
US8642618B2 (en) 2014-02-04
KR20100046188A (ko) 2010-05-06
CA2691632A1 (en) 2009-01-15
WO2009008539A1 (en) 2009-01-15
JP5558348B2 (ja) 2014-07-23
KR20150038739A (ko) 2015-04-08
JP2014185161A (ja) 2014-10-02
US20140121241A1 (en) 2014-05-01
JP2010533166A (ja) 2010-10-21
AR067446A1 (es) 2009-10-14
EP2162134A1 (en) 2010-03-17
TW200908973A (en) 2009-03-01

Similar Documents

Publication Publication Date Title
CN101754758B (zh) 一种用于治疗阿尔茨海默氏症的包含喹诺酮衍生物和多奈哌齐的药物
CN101778630A (zh) 用于治疗脂肪肝的包括西洛他唑的喹诺酮衍生物
SK7502002A3 (en) Pharmaceutical combinations
US20080249133A1 (en) Use of Substituted 2-Thio-3,5-Dicyano-4-Phenyl-6-Aminopyridines In the Treatment of Nausea and Vomiting
EP2181707A1 (en) Combined use of an alpha-adrenergic receptor antagonist and an anti-muscarinic agent
CN101500567B (zh) P38激酶抑制剂治疗精神障碍的用途
JP2006176503A (ja) 脳血管障害を伴うアルツハイマー病治療薬
CN108771662A (zh) 紫檀芪在制备防治高尿酸肾病的药物中的用途
CN101677998B (zh) 包含西洛他唑的治疗精神分裂症药物
JPH01265027A (ja) 肝疾患治療剤
EP2184284B1 (en) Preventive, inhibitor or remedy for cerebral aneurysm comprising ibudilast as an active ingredient
CN117396202A (zh) 给药方案
KR101442874B1 (ko) 만성 폐색성 폐질환 치료제
CN113209108B (zh) 7-氨基头孢烷酸或其衍生物在制备治疗和/或预防脂质代谢异常相关性疾病药物中的应用
WO2025087460A1 (zh) 一种吡啶并吡唑衍生物药物组合物及其应用
JP6714225B2 (ja) 肝細胞癌の予防又は治療のための医薬
CN102026638A (zh) 喹诺酮和肉碱的组合
WO2003089426A1 (en) Medicine for prevention and/or therapy of disseminated intravascular coagulation syndrome
JP2002255818A (ja) 脳血管障害後発症肺炎の予防剤
HK1140136B (en) A medicament for treating chronic obstructive pulmonary disease

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20100714